CSPC Pharmaceutical Unit to Divest 30% Stake in Connected Party Deal

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group said a non-wholly owned subsidiary has agreed to sell its entire 30.0704% equity stake in a target company for RMB230 million to a purchaser connected to director and substantial shareholder Cai Dong Chen. The disposal price is based on an independent valuation and, once completed, will leave CSPC and the selling subsidiary with no remaining interest in the target company.

Because the buyer is an associate of a connected person, the transaction is classified as a connected deal under Hong Kong listing rules and is subject to reporting and announcement requirements, though exempt from circular and independent shareholder approval thresholds. Completion hinges on approval by the vendor’s minority shareholders by 30 June 2026, with related-party CSPC subsidiaries abstaining, meaning the transaction may not proceed and investors are urged to exercise caution when dealing in the company’s securities.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group operates through various subsidiaries, with a focus on developing, manufacturing, and selling pharmaceutical products in China and international markets, and actively manages its portfolio via equity investments and disposals.

Average Trading Volume: 119,754,449

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$115.7B

Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.